Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Cediranib + Saracatinib clear cell renal cell carcinoma not applicable detail...
VHL over exp Cediranib + Saracatinib clear cell renal cell carcinoma no benefit detail...
SRC over exp Cediranib + Saracatinib clear cell renal cell carcinoma no benefit detail...
AKT1 wild-type Everolimus + RX-0201 clear cell renal cell carcinoma sensitive detail...
Unknown unknown PF-03446962 clear cell renal cell carcinoma not applicable detail...
Unknown unknown PT2385 clear cell renal cell carcinoma not applicable detail...
Unknown unknown Sorafenib + Temsirolimus clear cell renal cell carcinoma no benefit detail...
Unknown unknown Temsirolimus + Bevacizumab clear cell renal cell carcinoma no benefit detail...
Unknown unknown Bevacizumab + Sorafenib clear cell renal cell carcinoma no benefit detail...
VHL inact mut PT2399 clear cell renal cell carcinoma conflicting detail...
TP53 R248W VHL inact mut PT2399 clear cell renal cell carcinoma resistant detail...
Unknown unknown Pazopanib clear cell renal cell carcinoma not applicable detail...
Unknown unknown Pazopanib + Abexinostat clear cell renal cell carcinoma not applicable detail...
Unknown unknown Bevacizumab + Vorinostat clear cell renal cell carcinoma not applicable detail...
Unknown unknown Cabozantinib clear cell renal cell carcinoma not applicable detail...
Unknown unknown everolimus + pazopanib clear cell renal cell carcinoma no benefit detail...
Unknown unknown Epacadostat + Pembrolizumab clear cell renal cell carcinoma not applicable detail...
Unknown unknown girentuximab clear cell renal cell carcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00747305 Phase I Sunitinib Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery Terminated
NCT00831480 Phase II Everolimus Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal Terminated
NCT01038778 Phase Ib/II Entinostat Aldesleukin Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Active, not recruiting
NCT01099423 Phase III Sunitinib Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Unknown status
NCT01158521 Phase II Pazopanib Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer Completed
NCT01392183 Phase II Diphenhydramine Temsirolimus Pazopanib Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) Active, not recruiting
NCT01499121 Phase II Sunitinib Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule Completed
NCT01582204 Phase I Pazopanib Sunitinib Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma Active, not recruiting
NCT01599754 Phase III Axitinib Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Terminated
NCT01599832 Phase I Pazopanib Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer Terminated
NCT01684397 Phase Ib/II Pazopanib + Bevacizumab Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer Recruiting
NCT01835158 Phase II Cabozantinib Cabozantinib + Sunitinib Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Active, not recruiting
NCT01999972 Phase I Axitinib + Crizotinib A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors Active, not recruiting
NCT02060370 Phase II Sunitinib Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) Active, not recruiting
NCT02210117 Phase II Nivolumab Bevacizumab + Nivolumab Nivolumab + Ipilimumab Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) Active, not recruiting
NCT02293980 Phase I PT2385 PT2385 + Nivolumab A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma Active, not recruiting
NCT02307474 Phase I Pazopanib A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer Withdrawn
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Active, not recruiting
NCT02348008 Phase Ib/II Bevacizumab + Pembrolizumab Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma Active, not recruiting
NCT02386111 Phase Ib/II Sunitinib + Varlilumab A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Terminated
NCT02509507 Phase I Pembrolizumab + talimogene laherparepvec talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Recruiting
NCT02535533 Phase I Axitinib + Selenomethionine SLM + Axitinib for Clear Cell RCC Recruiting
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02575222 Phase I Nivolumab Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma Active, not recruiting
NCT02579811 Phase II Axitinib Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer Active, not recruiting
NCT02595918 Phase I Nivolumab Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer Recruiting
NCT02599324 Phase Ib/II Docetaxel Ibrutinib Everolimus Paclitaxel Cetuximab A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting
NCT02607553 Phase II mipsagargin Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed
NCT02626130 Phase I Tremelimumab Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC) Active, not recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting
NCT02667886 Phase Ib/II Axitinib X4P-001 Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma Active, not recruiting
NCT02837991 Phase Ib/II CDX-014 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma Terminated
NCT02853344 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Active, not recruiting
NCT02885649 Phase 0 Enzalutamide Enzalutamide Before Surgery in Treating Patients With Kidney Cancer Recruiting
NCT02947165 Phase I NIS793 + PDR001 NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02974738 Phase I PT 2977 A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors Recruiting
NCT02978404 Phase II Nivolumab Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases Recruiting
NCT02989714 Phase Ib/II Aldesleukin + Nivolumab Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer Recruiting
NCT03015740 Phase Ib/II MGCD516 + Nivolumab MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC) Recruiting
NCT03024996 Phase III Atezolizumab A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) Recruiting
NCT03035630 Phase II Avelumab Sunitinib Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma Withdrawn
NCT03108066 Phase II PT2385 PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Active, not recruiting
NCT03138512 Phase III Nivolumab + Ipilimumab A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) Recruiting
NCT03141177 Phase III Cabozantinib + Ipilimumab + Nivolumab Sunitinib Cabozantinib + Nivolumab A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) Recruiting
NCT03149159 Phase II Nivolumab + Ipilimumab Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab Withdrawn
NCT03170960 Phase Ib/II Atezolizumab + Cabozantinib Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03173560 Phase II Everolimus + Lenvatinib Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma Recruiting
NCT03200717 Phase II Pazopanib Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment Recruiting
NCT03260504 Phase I Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Recruiting
NCT03284385 Phase II Adavosertib Adavosertib in Treating Patients With SETD2-Deficient Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03294083 Phase I JX-594 + REGN2810 A Study of Recombinant Vaccinia Virus in Combination With REGN2810 for Renal Cell Carcinoma Recruiting
NCT03308396 Phase Ib/II Durvalumab + Guadecitabine Guadecitabine Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer Recruiting
NCT03334409 Phase II Pazopanib Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery Recruiting
NCT03438708 Phase II Axitinib Prior Axitinib as a Determinant of Outcome of Renal Surgery (PADRES) Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03679767 Phase II INCMGA00012 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Recruiting
NCT03680521 Phase II MGCD516 + Nivolumab Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma Recruiting
NCT03682289 Phase II AZD6738 + Olaparib Olaparib Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Recruiting
NCT03829111 Phase I Nivolumab + Ipilimumab CBM588 + Ipilimumab + Nivolumab CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer Not yet recruiting
NCT03875313 Phase Ib/II CB-839 + Talazoparib Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Recruiting